Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 7/20 | 0.53 |
| ▸ | VIPR1 | P32241 | 5/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | BACE1 | P56817 | 3/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.51 |
| ▸ | GLP1R | P43220 | 2/20 | 0.48 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30543189 | 1.00 | VIPR2 (0.53) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL29425538 | 0.98 | VIPR2 (0.51) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL29462368 | 0.97 | VIPR2 (0.50) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL30741250 | 0.97 | VIPR2 (0.56) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL29466598 | 0.94 | VIPR2 (0.54) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL29903357 | 0.88 | VIPR1 (0.54) | VIPR2VIPR1BACE1BACE2GLP1R | |
| SCHEMBL30168717 | 0.88 | F2 (0.55) | F2IL23R | |
| SCHEMBL29520980 | 0.86 | VIPR2 (0.54) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL29778027 | 0.86 | VIPR2 (0.54) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL31319514 | 0.86 | BACE1 (0.51) | BACE1BACE2IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852389-B | Gram-negative bacteria-targeted antibacterial peptide, chitosan nanoparticle thereof and application thereof | 东北农业大学 | 2025-04-22 | — | — | CN | disclosed |
| CN-118955636-A | Modified Fc-III peptide, antibody-lipid conjugate, synthesis method of bispecific antibody complex and application of bispecific antibody complex | 香港中文大学 | 2024-11-15 | — | — | CN | disclosed |
| CN-118852389-A | Gram-negative bacteria-targeted antibacterial peptide, chitosan nanoparticle thereof and application thereof | 东北农业大学 | 2024-10-29 | — | — | CN | disclosed |
| US-20240024504-A1 | SITE-SELECTIVE LYSINE ACETYLATION OF HUMAN IMMUNOGLOBULIN G AND IgG-RELATED PRODUCTS FOR IMMUNOTHERAPY | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2024-01-25 | — | — | US | disclosed |
| CN-115974977-A | Modified Fc-III peptide, antibody-lipid conjugate, synthesis method of bispecific antibody complex and application of bispecific antibody complex | 香港中文大学 | 2023-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024504-A1 | SITE-SELECTIVE LYSINE ACETYLATION OF HUMAN IMMUNOGLOBULIN G AND IgG-RELATED PRODUCTS FOR IMMUNOTHERAPY | FCGR3B, FCGR2A, FCGR1A | VIPR2 3552/4885VIPR1 3426/4885F2 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.